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Abstract
Background
Echocardiographic signs of constrictive physiology (CP) after pericardiocentesis are fre-
quently observed in malignancy patients. The purpose of the current study was to explore
whether features of CP after pericardiocentesis have prognostic impact in malignancy
patients with pericardial effusion (PE).
Methods
We retrospectively reviewed 467 consecutive patients who underwent pericardiocentesis at
our institution from January 2006 to May 2014. Among them, 205 patients with advanced
malignancy who underwent comprehensive echocardiography after the procedure com-
prised the study population. Co-primary end points were all-cause mortality (ACM) and
repeated drainage (RD) for PE. Patients were divided into four subgroups according to cyto-
logic result for malignant cells and CP (positive cytology with negative CP, both positive,
both negative, and negative cytology with positive CP).
Results
CP after pericardiocentesis was present in 106 patients (50%) at median 4 days after the
procedure. During median follow-up of 208 days, ACM and RD occurred in 162 patients
(79%) and 29 patients (14%), respectively. Cox regression analysis revealed that indepen-
dent predictors for ACM were male gender and positive cytology (all, p < 0.05). For RD, pre-
dictors were positive cytology, the absence of cardiac tamponade, and negative CP after
pericardiocentesis (all, p < 0.05). When the patients were divided into four subgroups,
patients with negative cytology and positive CP demonstrated the most favorable survival
(hazard ratio [HR]: 0.39, p = 0.005) and the lowest RD rates (HR: 0.07, p = 0.012).
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Conclusion
CP after pericardiocentesis is common, but does not always imply poor survival or the need
for RD in patients with advanced malignancies. On the contrary, the presence of CP in
patients with negative cytology conferred the most favorable survival and the lowest rate of
RD. Comprehensive echocardiographic evaluation for CP after pericardiocentesis would be
helpful for predicting prognosis in patients with advanced malignancies.
Introduction
Cardiac tamponade is an acute or subacute compression of the heart due to pericardial fluid
accumulation and can be life-threatening. The most common cause of cardiac tamponade is
malignancy, which is involved in> 50% of all tamponade cases[1]. Pericardiocentesis is lifesav-
ing in cases of cardiac tamponade; it alone frequently results in the resolution of large pericar-
dial effusion (PE) in malignancy patients, but recurrence is common[2–7].
Constrictive physiology (CP) is an echocardiographic criterion for the diagnosis of constric-
tive pericarditis and comprehensive transthoracic echocardiography has contributed to the
ability of physicians to easily detect constrictive pericarditis without invasive catheterization or
operative findings. Classic constrictive pericarditis is known to be a progressive and debilitating
condition and is characterized by pericardial fibrosis and calcification[8]. Meanwhile, echocar-
diographic CP is not only found in patients with symptomatic constrictive pericarditis, but is
also more commonly observed in rather benign conditions, especially in post-cardiac surgery
patients without clinical constrictive pericarditis when assessed with comprehensive examina-
tion[9]. Postoperative CP after cardiac surgery has been reported to be relatively common and
is usually transient and benign[9].
The predictors of mortality and recurrence of PE following pericardiocentesis in malignancy
patients are not yet fully understood. Survival of patients with malignancy and PE has been
reported to be mainly associated with the extent of the disease, reflected by positive results on
PE cytology[10]. Although CP is also frequently observed in malignancy patients after pericar-
diocentesis, few data are available regarding the clinical implications of echocardiographically
observed CP after pericardiocentesis. Therefore, the purpose of the current study was to inves-
tigate whether features of CP after pericardiocentesis have prognostic implications for all-cause
mortality (ACM) and repeated drainage (RD) of PE after pericardiocentesis in malignancy
patients. We hypothesized that the prognosis of malignancy patients with large PE would be
different according to the presence of CP and cytologic results for malignant cells after
pericardiocentesis.
Methods
Patient population
We retrospectively reviewed data from 467 patients who underwent pericardiocentesis due to
PE at our institution from January 2006 to May 2014. After excluding 232 patients without
malignancies, 12 patients without postoperative comprehensive echocardiography, 9 patients
with acute leukemia, 4 patients with lymphoma and 5 patients with stage I, II or complete
remission status, the remaining 205 patients with advanced solid malignancies who underwent
comprehensive echocardiography after the pericardiocentesis comprised the study population.
Charts were systemically reviewed for data relating to cancer stage, co-morbidities, and
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laboratory studies such as hemoglobin, creatinine, and C-reactive protein (CRP). Cardiac tam-
ponade was defined by combining clinical and echocardiographic criteria[11]. Characteristic
clinical criteria included venous hypotension, pulsus paradoxus, or arterial hypotension in the
absence of other possible causative conditions and resolution of the syndrome on removal of
PE. Along with the characteristic clinical criteria, echocardiographic criteria, such as chamber
collapse, mitral inflow respiratory variation, and inferior vena cava plethora, were also assessed
to diagnose cardiac tamponade [12].
Co-primary end points were ACM and RD. All PE was confirmed by pre-procedural echo-
cardiography. Pericardiocentesis was performed under echocardiographic or fluoroscopic
guidance. Prolonged PE drainage was done for all patients as follows: The pericardial catheter
was left in place until complete drainage of PE was obtained, which was defined as drainage
of 40 ml over a 24-hour period and a follow-up 2-dimentional echocardiogram with residual
pericardial effusion, which was non-circumferential and< 1 cm in size. Values of carcinoem-
bryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21–1) were measured in drained
pericardial effusion. None of the patients were treated by instillation of sclerosing agent follow-
ing pericardiocentesis. Patients were divided into four subgroups according to cytologic result
for malignant cells and echocardiographic CP after pericardiocentesis (positive cytology with
negative CP, both positive, both negative, and negative cytology with positive CP). Patient rec-
ords/information was anonymized and de-identified prior to analysis. This study was approved
by the Institutional Review Board of Yonsei University, Severance Hospital, Seoul, Korea.
Echocardiographic measurement
Standard 2-dimensional and Doppler echocardiographic assessments were performed. The
echocardiographic images of the included patients were reanalyzed by 2 experienced echocar-
diographers who were blinded to patient clinical data. Left ventricular (LV) internal diameter,
septal thickness, and LV posterior wall thickness were measured at end-diastole. LV mass was
calculated as recommended by the American Society of Echocardiography[13], and LV mass
was indexed for body surface area. The left atrial volume was calculated from the parasternal
long-axis view and apical four-chamber view using the prolate ellipse method[14] and was
indexed for the body surface area. The mitral inflow velocities were obtained by pulsed wave
Doppler in the apical four-chamber view. The mitral early diastolic velocity (E) was measured.
The peak early diastolic mitral annular (E') velocity was measured from the septal mitral annu-
lus; we then calculated the E/E' ratio. A moderate pericardial effusion was considered to be
present when the sum of the diastolic echo-free anterior and posterior spaces was 1 to 2 cm
and large when it was greater than 2 cm[12]. CP was defined as follows: respiratory-related
ventricular septal shift, dilated inferior vena cava (maximal diameter> 21 mm), a respiratory
variation of 25% or more in the mitral inflow E velocity and increased diastolic flow reversal
with expiration in the hepatic vein, and mitral septal annulus velocity of more than 7 cm/sec
[15,16].
Pericardial wall thickening and tumor infiltration
Maximal pericardial thickness was measured using computed tomography (CT) with contrast
that enabled assessment of the whole pericardium. Pericardial thickening was defined as a peri-
cardial thickness of more than 4 mm [11,17]. Irregular nodular thickening or tumor infiltration
of the pericardium was assessed using CT findings to determine whether there was metastatic
involvement of the pericardium [18].
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Statistical analysis
Distribution of relevant variables was reported either as a percentage or as the mean ± standard
deviation. The groups were compared using χ2 statistics for categorical variables and the Stu-
dent t test for continuous variables. Multivariable Cox proportional hazard analysis was
employed to determine independent variables for ACM and RD, with variables with P< 0.3 in
univariate analysis between the patients with and without primary outcomes as covariates. For
Kaplan-Meier analysis, we analyzed all combined events, ACM and RD by time to the first
event. P-values< 0.05 were considered statistically significant.
Results
Patient characteristics
The indications for drainage were cardiac tamponade in 167 patients (81%), relief of an
impending cardiac tamponade in 33 patients (16%), and diagnostic purposes in patients with-
out a clear etiology in five patients (2%). Patient characteristics and comparison of characteris-
tics in patient groups according to all combined events, ACM and RD are shown in Table 1. Of
the 205 patients included in this study, there were 121 men and 84 women with a mean age of
58 ± 13 years. CP after pericardiocentesis was present in 102 patients (50%) at median 4 days
(1–27 days) after the procedure. During a median follow-up of 208 days (1–2408 days), ACM
and RD occurred in 162 patients (79%) and 29 patients (14%), respectively. Indication for RD
was cardiac tamponade in all the 29 patients with RD.
All combined events including ACM and RD occurred in 166 patients (81%). There were no
significant differences between the patients with and without all combined events in age, gen-
der, type of cancer, prevalence of hypertension, diabetic mellitus, previous thoracic irradiation,
or cardiac tamponade and echocardiographic parameters. Positive cytology was more preva-
lent in patients with events (p = 0.010). The prevalence of CP was largely comparable between
the patients with and without events. When patients were divided into 4 subgroups according
to the results of cytology and CP, patients with negative cytology and positive CP demonstrated
the lowest all combined events (p< 0.001). Similarly, there were no significant differences in
various clinical and echocardiographic characteristics between the survivor and non-survivor
groups, except positive cytology (p = 0.045). Patients with negative cytology and positive CP
also showed the lowest ACM compared to other groups (p = 0.001).
There were no significant differences between patients with and without RD in age, gender,
type of cancer, stage of cancer, or prevalence of hypertension, diabetic mellitus, previous tho-
racic irradiation and cardiac tamponade. The prevalence of positive cytology was also not sig-
nificantly different between the two groups, but CP was more frequently observed in patients
without RD compared to those with RD (p = 0.010). E' velocity was higher and E/E' was lower
in patients without RD (p = 0.002 and p = 0.010, respectively), reflecting exaggerated E' veloc-
ity, which is a sign of CP. When patients were divided into four subgroups, prevalence RD was
the lowest in patients with negative cytology and positive CP (p = 0.012).
Predictors for ACM and RD
Multivariate Cox regression analysis was performed to investigate independent predictors for
ACM and RD. Predictors for ACM are shown in Table 2. In multivariate Cox regression analy-
sis, the independent predictors for ACM were male gender (HR; hazard ratio: 1.48, 95% CI;
confidential interval: 1.07–2.05, p = 0.019) and positive cytology (HR: 1.86, 95% CI: 1.28–2.70,
p = 0.001). In the model using subgroups according to CP and cytology, patients with negative
cytology and positive CP were associated with the lowest risk for ACM compared to those with
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Table 1. Comparison of characteristics in the patient groups according to all combined events, all-causemortality and repeated drainage of peri-
cardial effusion.
Variable All combined events All-cause mortality Repeated drainage
Without
events
(n = 39)
With events
(n = 166)
P-
value
Survivor
(n = 43)
Non-
survivor
(n = 162)
P-
value
No repeated
drainage
(n = 176)
Repeated
drainage
(n = 29)
P-
value
Age, years 57 ± 14 58 ± 13 0.857 58 ± 13 58 ± 13 0.936 58 ± 13 56 ± 14 0.337
Male, n (%) 19 (49) 102 (61) 0.146 21 (49) 100 (62) 0.127 108 (66) 13 (45) 0.093
Types of cancer, n (%) 0.821 0.803 0.595
Lung cancer 22 (56) 93 (56) 26 (60) 89 (55) 98 (56) 17 (59)
Breast cancer 5 (13) 19 (11) 5 (12) 19 (12) 20 (11) 4 (14)
Stomach cancer 3 (7) 18 (11) 3 (7) 18 (11) 17 (10) 4 (14)
Esophageal cancer 2 (5) 4 (2) 2 (5) 4 (2) 4 (2) 2 (7)
Colon cancer 1 (3) 5 (3) 1 (2) 5 (3) 6 (3) 0 (0)
Cervical cancer 2 (5) 3 (2) 2 (5) 3 (2) 5 (3) 0 (0)
Other* 4 (10) 24 (14) 4 (9) 24 (15) 26 (15) 2 (7)
Cancer stage, n (%) 0.977 0.815 0.107
III 5 (13) 21 (13) 5 (12) 21 (13) 25 (14) 1 (3)
IV 34 (87) 145 (87) 38 (88) 141 (87) 151 (86) 28 (97)
Hypertension, n (%) 16 (41) 55 (33) 0.351 18 (42) 53 (33) 0.263 62 (35) 9 (31) 0.660
Diabetes mellitus, n (%) 2 (5) 18 (11) 0.279 2 (5) 18 (11) 0.204 19 (11) 1 (3) 0.320
Previous thoracic
irradiation, n (%)
12 (31) 40 (24) 0.389 12 (28) 40 (25) 0.667 45 (26) 7 (24) 0.870
Laboratory
Hemoglobin (g/dL) 11.1 ± 2.1 11.0 ± 1.8 0.814 11.1 ± 2.0 11.0 ± 1.8 0.751 11.0 ± 1.9 11.5 ± 1.5 0.183
Creatinine (g/mL) 0.82 ± 0.40 0.99 ± 1.46 0.465 0.80 ± 0.39 1.00 ±1.47 0.385 1.00 ± 1.42 0.70 ± 0.19 0.257
Cardiac tamponade, n
(%)
30 (77) 137 (83) 0.417 31 (72) 136 (84) 0.075 147 (84) 20 (69) 0.062
Pericardial effusion,
amount
0.744 0.590 0.324
Moderate 4 (3) 14 (8) 5 (12) 13 (8) 16 (9) 2 (7)
Large 35 (70) 152 (92) 38 (88) 149 (92) 160 (91) 27 (93)
Post-pericardiocentesis
echocardiographic
LV end-diastolic
diameter (mm)
45.1 ± 5.3 45.0 ± 5.5 0.956 44.9 ± 5.3 45.1 ± 5.5 0.823 45.1 ± 5.2 44.5 ± 6.7 0.608
LV end-systolic
diameter (mm)
30.0 ± 5.1 30.6 ± 5.7 0.552 29.8 ± 5.3 30.7 ± 5.7 0.424 30.6 ± 5.2 29.6 ± 7.3 0.392
LV ejection fraction
(%)
65.2 ± 9.1 62.5 ± 11.1 0.190 65.0 ± 9.8 62.4 ± 16.4 0.191 62.7 ± 10.4 64.8 ± 12.2 0.357
E velocity (cm/sec) 70.6 ± 16.6 68.7 ± 16.3 0.594 68.9 ± 16.6 69.3 ± 16.4 0.907 69.3 ± 16.6 68.5 ± 15.2 0.852
E' velocity (cm/sec) 7.9 ± 2.6 7.2 ± 2.5 0.249 7.7 ± 2.6 7.3 ± 2.5 0.360 7.6 ± 2.6 6.0 ± 2.0 0.011
E/E' 10.1 ± 4.3 10.9 ± 5.2 0.464 10.0 ± 4.3 11.0 ± 5.2 0.387 10.1 ± 4.1 14.0 ± 7.8 0.002
CP, n (%) 16 (41) 86 (52) 0.226 18 (42) 84 (52) 0.244 94 (53) 8 (28) 0.010
PE ﬂuid cytology, n (%)
Positive for malignant
cells
19 (49) 117 (70) 0.010 23 (53) 113 (70) 0.045 115 (65) 21 (72) 0.455
Subgroups according to
cytology and CP, n (%)
< 0.001 0.001 0.012
Cytology (+), CP (–) 11 (28) 36 (22) 13 (30) 34 (21) 34 (19) 13 (45)
Cytology (+), CP (+) 7 (18) 81 (49) 9 (21) 79 (49) 80 (45) 8 (28)
Cytology (–), CP (–) 10 (26) 36 (22) 10 (23) 36 (22) 39 (22) 7 (24)
(Continued)
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both positive results, even after adjusting for gender and cardiac tamponade (HR: 0.39, 95% CI:
0.20–0.72, p = 0.005).
Predictors for RD are shown in Table 3. Positive cytology was also an independent predictor
for RD in multivariate Cox analysis (p = 0.005). Moreover, the presence of cardiac tamponade
and CP after pericardiocentesis were independent predictors for 60% and 66% risk reduction
respectively and positive cytology was 3-fold increased risk for RD in the multivariate analysis
(p = 0.037, p = 0.012, and p = 0.015, respectively). In the model using subgroups according to
CP and cytology, patients with negative cytology and positive CP were associated with the low-
est risk for RD compared to those with positive cytology and negative CP, even after adjusting
for gender and cardiac tamponade (HR: 0.07, 95% CI: 0.01–0.56, p = 0.012).
Comparisons of outcomes according to the results of CP and cytology
Fig 1 shows the comparison of all combined events according to the presence of CP and posi-
tive cytology in the entire studied malignancy population. There was no significant difference
in all combined event-free survival in patients with and without CP (Fig 1A). All combined
events were more frequent in patients with positive cytology than in those with negative
Table 1. (Continued)
Variable All combined events All-cause mortality Repeated drainage
Without
events
(n = 39)
With events
(n = 166)
P-
value
Survivor
(n = 43)
Non-
survivor
(n = 162)
P-
value
No repeated
drainage
(n = 176)
Repeated
drainage
(n = 29)
P-
value
Cytology (–), CP (+) 11 (28) 13 (8) 11 (26) 13 (8) 23 (13) 1 (3)
*Other includes 4 hepatocellular carcinomas, 3 cholangiocarcinoma, 3 renal cell carcinoma, 3 pancreatic cancer, 3 sarcoma, 3 primary unknown cancer,
2 ovarian cancer, 2 parotid gland cancer, 2 malignant thymoma, 1 gallbladder cancer, 1 thyroid cancer, and 1 tonsillar cancer; PE, pericardial effusion; LV,
left ventricular; E, early diastolic mitral inﬂow; E', early diastolic mitral annular; CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.t001
Table 2. Cox regression analysis for predictors of all-cause death.
Predictor Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Model 1
Male gender 1.33 (0.97–1.83) 0.077 1.48 (1.07–2.05) 0.019
Cardiac tamponade 1.48 (0.97–2.25) 0.070 1.26 (0.82–1.94) 0.302
Cytology positive 1.85 (1.30–2.61) 0.001 1.86 (1.28–2.70) 0.001
CP positive 1.24 (0.91–1.70) 0.167 1.07 (0.78–1.46) 0.698
Model 2
Male gender 1.33 (0.97–1.83) 0.077 1.48 (1.07–2.05) 0.017
Cardiac tamponade 1.48 (0.97–2.25) 0.070 1.36 (0.88–2.11) 0.169
Subgroups according to CP and cytology
Cytology (+), CP (–) 1.0 - 1.0 -
Cytology (+), CP (+) 1.49 (0.99–2.23) 0.055 1.46 (0.97–2.20) 0.067
Cytology (–), CP (–) 0.83 (0.52–1.34) 0.444 0.85 (0.52–1.39) 0.518
Cytology (–), CP (+) 0.41 (0.21–0.78) 0.007 0.39 (0.20–0.74) 0.005
HR, hazard ratio; CI, conﬁdence interval; CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.t002
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cytology (Fig 1B). Fig 1C presents the difference in all combined event-free survival among the
subgroups according to cytology and CP. Among the four subgroups, patients with negative
cytology and positive CP showed the most favorable all event-free survival rates (p< 0.001).
Fig 2 presents ACM and RD according to cytology and CP. Similar to all combined events,
patients with negative cytology and positive CP showed the most favorable survival rates and
lowest RD rates. In contrast, positive cytology and negative CP showed the most unfavorable
survival rates and the highest RD rates among the four subgroups.
Since pericardial fluid cytology was an important predictor for all ACM and RD in Cox
regression analysis, we divided the population into two categories of positive and negative
cytology, and compared ACM and RD. Fig 3 shows a comparison of survival and RD according
to the presence of CP in positive cytology (Fig 2A and 2C) and negative cytology (Fig 2B and
2D) group. The survival rate was lower in the CP group compared to the non-CP group in the
positive cytology population (p = 0.017). However, in contrast, the survival rate was reversed
between CP and non-CP groups among the subgroup of negative cytology (p = 0.010). RD was
much higher in the non-CP group in the cytology positive population (p = 0.049), although it
was not significantly different among the negative-cytology group according to the presence of
CP. Patients with CP in positive cytology also demonstrated a very low rate of RD during fol-
low-up, which was almost similar to that of the cytology-negative group.
Pericardial thickening and tumor infiltration
CT for the thoracic area including the pericardium was performed for 180 patients among all
those included. Table 4 shows comparison of CT and clinical findings in patients with negative
or positive cytology according to the presence of CP in the subgroup who underwent chest CT.
Pericardial thickening was more frequent in the positive CP group among patients with nega-
tive cytology, as well as those with positive cytology (all, p< 0.001). Irregular pericardial nodu-
larity or pericardial tumor infiltration, suggesting malignant effusion, was more prevalent in
the CP group only in patients with positive cytology (p = 0.004). In contrast, its prevalence was
Table 3. Cox regression analysis for predictors of repeat drainage of pericardial effusion.
Predictor Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Model 1
Male gender 0.68 (0.33–1.41) 0.296 0.78 (0.37–1.65) 0.518
Cardiac tamponade 0.60 (0.27–1.31) 0.196 0.40 (0.17–0.95) 0.037
Cytology positive 1.95 (0.85–4.45) 0.114 3.01 (1.25–7.59) 0.015
CP positive 0.42 (0.19–0.95) 0.038 0.34 (0.15–0.79) 0.012
Model 2
Male gender 0.68 (0.33–1.41) 0.296 0.75 (0.36–1.58) 0.454
Cardiac tamponade 0.60 (0.27–1.31) 0.196 0.42 (0.18–0.96) 0.041
Subgroups according to CP and cytology
Cytology (+), CP (–) 1.0 - 1.0 -
Cytology (+), CP (+) 0.37 (0.15–0.90) 0.029 0.36 (0.15–0.87) 0.024
Cytology (–), CP (–) 0.46 (0.18–1.16) 0.098 0.36 (0.13–0.96) 0.040
Cytology (–), CP (+) 0.09 (0.01–0.67) 0.019 0.07 (0.01–0.56) 0.012
HR, hazard ratio; CI, conﬁdence interval; CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.t003
Constrictive Physiology after Pericardiocentesis in Malignancy
PLOS ONE | DOI:10.1371/journal.pone.0145461 December 21, 2015 7 / 14
lower in the CP group among cytology-negative patients, although this was not statistically sig-
nificant (37% vs. 24%, p = NS).
Fig 4 presents a comparison of CEA and CYFRA 21–1 in PE and serum CRP according to
presence of cytology and CP. CYFRA 21–1 measured in drained PE was significantly higher
in patients without CP compared to those with CP in the subgroup of patients with negative
cytology (p = 0.031). Serum CRP, a surrogate marker for systemic inflammation, demon-
strated higher values in patients with CP in both cytology-positive and cytology-negative
groups, although this was not statistically significant. In addition, in the overall study popula-
tion regardless of cytologic result, CRP was higher in CP groups than in non-CP groups
(70.2 ± 66.5 mg/L vs. 93.4 ± 83.0 mg/L, p = 0.038).
Discussion
The principal finding of the current study is that CP after pericardiocentesis demonstrated dif-
ferential impacts on ACM and RD in patients with advanced malignancies. The presence of CP
in patients with negative cytology conferred the most favorable survival and the lowest rate of
Fig 1. Comparison of all combined events according to the presence of constrictive physiology (A), positive cytology (B) and four groups divided
by the results of constrictive physiology and cytology.CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.g001
Fig 2. Comparison of survival (A) and repeated drainage for pericardial effusion (B) according to the
presence of constrictive physiology and positive cytology. CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.g002
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RD. In contrast, the presence of CP in patients with positive cytology was associated with poor
survival.
Cancer and PE
Malignant involvement of the pericardium is observed in 2–31% of autopsies of cancer
patients,[19] and pericardial disease is a relatively common complication of malignancy that
may lead to fatal cardiac tamponade. A large amount of PE is frequently shown in malignancy
patients, and one of the leading etiologies of PE requiring pericardiocentesis is malignancy[20].
Fig 3. Comparison of survival and repeated drainage for pericardial effusion according to the
presence of constrictive physiology. Patients with positive cytology (A, C) and patients with negative
cytology (B, D). CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.g003
Table 4. Comparison of computed tomography and clinical findings in patients with negative or positive cytology according to the presence of
constrictive physiology in the subgroup of 180 patients who underwent chest computed tomography.
Variables Cytology positive (n = 120) Cytology negative (n = 60)
CP negative
(n = 47)
CP positive
(n = 73)
P-
value
CP negative
(n = 43)
CP positive
(n = 17)
P-
value
Pericardial thickening, n (%) 11 (23) 58 (79) <0.001 4 (16) 12 (71) <0.001
Irregular pericardial nodularity or pericardial tumor
inﬁltration, n (%)
30 (64) 63 (86) 0.004 16 (37) 4 (24) 0.311
All-cause mortality, n (%) 37 (79) 70 (96) 0.011 41 (95) 8 (47) 0.012
Repeated drainage, n (%) 14 (30) 7 (10) 0.003 7 (16) 1 (6) 0.669
CP, constrictive physiology.
doi:10.1371/journal.pone.0145461.t004
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Meanwhile, PE in malignancy patients does not always guarantee a malignant PE, and the dif-
ferentiation of malignant PE from nonmalignant PE is not easy, contrary to our expectation.
Nonmalignant pericardial disease may be found in as many as 7% of the patients with malig-
nancies at postmortem examination and a significant proportion of patients with pericardial
disease and malignancies have a nonmalignant or radiation-related cause of pericardial disease
[21].
Currently, the diagnosis of malignant effusion largely depends on cytologic or pathologic
examination. Although it has been reported that catheter-based cytology is not inferior to sur-
gical biopsy by pericardiectomy for the diagnosis of malignant PE[22,23], cytologic examina-
tion has been shown to be diagnostic of malignancy only in about 85% of patients[21].
Therefore, 15% of malignant effusions can present false-negative results on pericardial fluid
cytologic examination.
CP after pericardiocentesis
CP is an echocardiographic finding suggesting constrictive pericarditis. However, it is not only
found in patients with symptomatic constrictive pericarditis but also more commonly observed
in rather benign conditions, especially in post-cardiac surgery patients when assessed with a
comprehensive echocardiographic examination[9]. CP after pericardiocentesis is a hallmark of
effusive-constrictive pericarditis, an uncommon pericardial syndrome in which constriction of
the heart by the visceral pericardium occurs in the presence of tense effusion in a free pericar-
dial space[24]. However, it is not clear whether all CPs in the current study resulted from effu-
sive-constrictive pericarditis, as it is a relatively uncommon disease. The prevalence of effusive-
constrictive pericarditis has been reported to be 6.9% among patients with clinical tamponade
[24] in contrast to our study population, which had a high prevalence of CP after pericardio-
centesis of up to 50%. Therefore, in the current study, CP may be associated with various etiol-
ogies, such as effusive-constrictive pericarditis, transient pericarditis, and restrictive motion of
the pericardium due to direct tumor invasion, all of which are suggested by the various CT
findings of this study.
CP in malignancies and survival
We found that positive cytology was associated with ACM, similar to the previous study[10].
Moreover, positive cytology was also related to RD, as expected. However, interestingly,
Fig 4. Comparison of pericardial effusion carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21–1) tumor markers (A, B) and
serumC-reactive protein (C) according to the presence of constrictive physiology and cytology.CP, constrictive physiology; CEA, carcinoembryonic
antigen; CYFRA 21–1, cytokeratin fragment 19; CRP, C-reactive protein.
doi:10.1371/journal.pone.0145461.g004
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features of CP after pericardiocentesis showed a differential prognostic impact according to
cytology results. In patients with positive cytology, CP was associated with unfavorable sur-
vival, in contrast to patients with negative cytology who showed favorable survival outcomes
with CP. This differential impact of CP might result from the different pathogeneses that lead
to the development of CP in malignant PE and nonmalignant PE.
CP in malignant PE might result from the restricted motion of the pericardium due to
infiltration of cancer cells and adhesion of the pericardium to the myocardium with tumor
invasion rather than inflammation. Therefore, in positive cytology patients, CP implies broad
and wide invasion of the tumor to the pericardium and might be associated with high ACM,
as also shown in higher prevalence of irregular pericardial nodularity or pericardial tumor
infiltration on CT. On the contrary, nonmalignant pericardial effusions, such as radiation-
induced pericarditis, idiopathic pericarditis, drug-induced pericarditis and infection might
be associated with pericardial inflammation and resultant CP. The survival of patients with
malignancy and nonmalignant PE has been shown to be better than for those with malignant
pericarditis[21]. This subgroup of patients which can be identified by negative cytology with
positive CP might have favorable survival in the current study, since the etiology of CP is not
malignant.
Another distinct group, patients with both negative cytology and CP showed high ACM
during follow-up, which is largely comparable to that of cytology-positive patients. We suggest
that this subgroup of patients includes patients with false negative cytologic results for malig-
nant cells, and therefore, they showed poor outcomes in ACM. The high prevalence of irregular
pericardial nodularity and pericardial tumor infiltration on CT images and the higher values of
PE tumor markers in non-CP patients with negative cytology might support our hypothesis.
Thus, our data also suggest mixed etiologies of CP in malignancy patients and potential differ-
ences between CP and non-CP groups in patients with negative cytology.
CP and recurrence of PE
Retrospective studies have shown that simple pericardiocentesis in patients with malignant PE
have recurrence rates are as high as 90%[2–7], and the recurrence rate was much greater in
patients with malignant PE compared with those without malignancy. Therefore, several
researchers even recommend surgical pericardiotomy as the definitive treatment for malignant
PE. Several studies have been performed to identify the predictors for PE recurrence. The
absence of extended catheter drainage, incomplete drainage, loculated effusions and malig-
nancy have been suggested to be predictors for recurrence in PE[3]. The RD of PE was only
14% in the studied population, although all studied patients were diagnosed with advanced
malignancies that were usually associated with high recurrence of PE. Tsang et al.[4] reported
that the recurrence rate of PE or persistent drainage that necessitated secondary management
was low, down to 11.5% when pericardiocentesis was performed with extended catheter drain-
age. As the same method was performed in our study population as well, extended catheter
drainage for managing PE might be crucial to avoid recurrent PE in patients with advanced
malignancy.
In the current study, we found that the presence of CP predicted a very low rate of RD for
both positive and negative cytology. The reason for this phenomenon is not clear. One possible
explanation may be that the long-term survival rate was poorest in the positive-cytology group;
therefore, the chances of RD were low due to the limited life expectancy of the population with
malignant PE. Therefore, the wisest strategy appears to be simply monitoring the cases clini-
cally and, if the large PE recurs, draining the PE by employing simple pericardiocentesis alone
rather than by aggressive interventions such as balloon pericardiotomy or surgical drainage in
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populations with both positive results, which suggest advanced cancer with pericardial invasion
and thereby indicate a low rate of long-term survival.
Another possible explanation for the low incidence of RD is that the etiology of PE in
patients with CP may be different from those without CP, which is associated with transient
inflammation of the pericardium and may be transient itself. This theory can be supported by
the CT findings of the patients with negative cytology and positive CP, which showed the low-
est prevalence of irregular pericardial nodularity or pericardial tumor infiltration and the low-
est prevalence of RD. In addition, the fact that CRP level was higher in the CP group than in
the non-CP group regardless of cytologic result also advocates the theory that CP might imply
an inflammatory process that would be associated with a low rate of RD. This phenomenon
also explains the lower RD rate in patients with both positive cytology and CP compared to
those with positive cytology and negative CP. In fact, as expected, patients with negative cytol-
ogy and positive CP demonstrated the lowest PE tumor marker values and the highest CRP
levels. Therefore, we also suggest that CP in negative cytology might be associated with inflam-
mation rather than malignant effusion. Further studies investigating inflammatory markers in
PE and applying anti-inflammatory medications for those patients would be helpful in identi-
fying the role of inflammation of the pericardium and effusion in the recurrence of large PE in
patients with malignancies.
Limitations
The main limitation of the current study is that this is a retrospective study. Pericardial effusion
in cancer patients is frequently related to various clinical conditions, such as radiation, inflam-
mation, opportunistic infections, drugs, hypoalbuminemia, and involvement of the lymphatic
system. However, due to retrospective nature of the current study and the complexity of the
study population (specifically, variance in chemotherapy regimens and general conditions), it
was difficult to describe our observations in a consistent manner. The choice of imaging, proce-
dural technique, and the duration of pericardial catheter drainage were all operator dependent.
The types of cancer were varied, although lung cancer was the most common. This study was
performed in malignancy patients requiring pericardiocentesis, and the result of this study can-
not be directly applied to other population without malignancies or small amounts of pericardial
effusion. Clinical findings suggesting symptomatic constrictive pericarditis were lacking due to
limited medical records associated with this retrospective analysis covering a long period.
Conclusions
CP after pericardiocentesis is common, but does not always imply poor survival or the need for
RD in patients with malignancies. On the contrary, CP in patients with negative cytology
showed favorable survival and low rate of RD for PE. Comprehensive echocardiographic evalu-
ation for CP after pericardiocentesis would be helpful for predicting prognosis in patients with
advanced malignancies.
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